133 related articles for article (PubMed ID: 38310905)
1. Invasive pneumococcal disease 3 years after introduction of a reduced 1 + 1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study.
Bertran M; D'Aeth JC; Abdullahi F; Eletu S; Andrews NJ; Ramsay ME; Litt DJ; Ladhani SN
Lancet Infect Dis; 2024 May; 24(5):546-556. PubMed ID: 38310905
[TBL] [Abstract][Full Text] [Related]
2. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
[TBL] [Abstract][Full Text] [Related]
3. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.
Waight PA; Andrews NJ; Ladhani SN; Sheppard CL; Slack MP; Miller E
Lancet Infect Dis; 2015 May; 15(5):535-43. PubMed ID: 25801458
[TBL] [Abstract][Full Text] [Related]
4. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018.
Andrews N; Kent A; Amin-Chowdhury Z; Sheppard C; Fry N; Ramsay M; Ladhani SN
Vaccine; 2019 Jul; 37(32):4491-4498. PubMed ID: 31272872
[TBL] [Abstract][Full Text] [Related]
6. Invasive Pneumococcal Disease Following the Introduction of 13-Valent Conjugate Vaccine in Children in New York City From 2007 to 2012.
Farnham AC; Zimmerman CM; Papadouka V; Konty KJ; Zucker JR; Nattanmai GV; Jose S; Rosen JB
JAMA Pediatr; 2015 Jul; 169(7):646-52. PubMed ID: 25938798
[TBL] [Abstract][Full Text] [Related]
7. Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec.
De Wals P; Lefebvre B; Deceuninck G; Longtin J
Vaccine; 2018 Jan; 36(3):421-426. PubMed ID: 29224962
[TBL] [Abstract][Full Text] [Related]
8. Invasive Pneumococcal Disease in UK Children <1 Year of Age in the Post-13-Valent Pneumococcal Conjugate Vaccine Era: What Are the Risks Now?
Kent A; Makwana A; Sheppard CL; Collins S; Fry NK; Heath PT; Ramsay M; Ladhani SN
Clin Infect Dis; 2019 Jun; 69(1):84-90. PubMed ID: 30281069
[TBL] [Abstract][Full Text] [Related]
9. Pneumococcal lineages associated with serotype replacement and antibiotic resistance in childhood invasive pneumococcal disease in the post-PCV13 era: an international whole-genome sequencing study.
Lo SW; Gladstone RA; van Tonder AJ; Lees JA; du Plessis M; Benisty R; Givon-Lavi N; Hawkins PA; Cornick JE; Kwambana-Adams B; Law PY; Ho PL; Antonio M; Everett DB; Dagan R; von Gottberg A; Klugman KP; McGee L; Breiman RF; Bentley SD;
Lancet Infect Dis; 2019 Jul; 19(7):759-769. PubMed ID: 31196809
[TBL] [Abstract][Full Text] [Related]
10. Invasive pneumococcal disease due to 22F and 33F in England: A tail of two serotypes.
Amin-Chowdhury Z; Groves N; Sheppard CL; Litt D; Fry NK; Andrews N; Ladhani SN
Vaccine; 2021 Apr; 39(14):1997-2004. PubMed ID: 33715901
[TBL] [Abstract][Full Text] [Related]
11. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study.
Ladhani SN; Collins S; Djennad A; Sheppard CL; Borrow R; Fry NK; Andrews NJ; Miller E; Ramsay ME
Lancet Infect Dis; 2018 Apr; 18(4):441-451. PubMed ID: 29395999
[TBL] [Abstract][Full Text] [Related]
12. Characteristics and Serotype Distribution of Childhood Cases of Invasive Pneumococcal Disease Following Pneumococcal Conjugate Vaccination in England and Wales, 2006-2014.
Oligbu G; Collins S; Andrews N; Sheppard CL; Fry NK; Slack MPE; Borrow R; Ladhani SN
Clin Infect Dis; 2017 Oct; 65(7):1191-1198. PubMed ID: 29309553
[TBL] [Abstract][Full Text] [Related]
13. Serotypes and Clonal Composition of Streptococcus pneumoniae Isolates Causing IPD in Children and Adults in Catalonia before 2013 to 2015 and after 2017 to 2019 Systematic Introduction of PCV13.
Redin A; Ciruela P; de Sevilla MF; Gomez-Bertomeu F; Gonzalez-Peris S; Benitez MA; Trujillo G; Diaz A; Jou E; Izquierdo C; Perez-Moreno MO; Moraga-Llop F; Olsina M; Vinado B; Sanfeliu E; Garcia A; Gonzalez-di Lauro S; Garcia-Garcia JJ; Dominguez A; Sa-Leao R; Muñoz-Almagro C;
Microbiol Spectr; 2021 Dec; 9(3):e0115021. PubMed ID: 34878302
[TBL] [Abstract][Full Text] [Related]
14. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.
Lepoutre A; Varon E; Georges S; Dorléans F; Janoir C; Gutmann L; Lévy-Bruhl D; ;
Vaccine; 2015 Jan; 33(2):359-66. PubMed ID: 25448105
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of Invasive Pneumococcal Disease Caused by Emerging Serotypes After the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in England: A Prospective Observational Cohort Study, 2014-2018.
Amin-Chowdhury Z; Collins S; Sheppard C; Litt D; Fry NK; Andrews N; Ladhani SN
Clin Infect Dis; 2020 Nov; 71(8):e235-e243. PubMed ID: 31955196
[TBL] [Abstract][Full Text] [Related]
16. Reduction of invasive pneumococcal disease 3 years after the introduction of the 13-valent conjugate vaccine in the Oxfordshire region of England.
Moore CE; Paul J; Foster D; Mahar SA; Griffiths D; Knox K; Peto TE; Walker AS; Crook DW;
J Infect Dis; 2014 Oct; 210(7):1001-11. PubMed ID: 24719477
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease among children in the United States between 2010 and 2019: An indirect cohort study.
Andrejko KL; Gierke R; Rowlands JV; Rosen JB; Thomas A; Landis ZQ; Rosales M; Petit S; Schaffner W; Holtzman C; Barnes M; Farley MM; Harrison LH; McGee L; Chochua S; Verani JR; Cohen AL; Pilishvili T; Kobayashi M
Vaccine; 2024 Jun; 42(16):3555-3563. PubMed ID: 38704263
[TBL] [Abstract][Full Text] [Related]
18. Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England.
van Hoek AJ; Sheppard CL; Andrews NJ; Waight PA; Slack MP; Harrison TG; Ladhani SN; Miller E
Vaccine; 2014 Jul; 32(34):4349-55. PubMed ID: 24657717
[TBL] [Abstract][Full Text] [Related]
19. Persistent Circulation of Vaccine Serotypes and Serotype Replacement After 5 Years of Infant Immunization With 13-Valent Pneumococcal Conjugate Vaccine in the United Kingdom.
Kandasamy R; Voysey M; Collins S; Berbers G; Robinson H; Noel I; Hughes H; Ndimah S; Gould K; Fry N; Sheppard C; Ladhani S; Snape MD; Hinds J; Pollard AJ
J Infect Dis; 2020 Mar; 221(8):1361-1370. PubMed ID: 31004136
[TBL] [Abstract][Full Text] [Related]
20. Serotypes, antimicrobial susceptibility, and molecular epidemiology of invasive and non-invasive Streptococcus pneumoniae isolates in paediatric patients after the introduction of 13-valent conjugate vaccine in a nationwide surveillance study conducted in Japan in 2012-2014.
Nakano S; Fujisawa T; Ito Y; Chang B; Suga S; Noguchi T; Yamamoto M; Matsumura Y; Nagao M; Takakura S; Ohnishi M; Ihara T; Ichiyama S
Vaccine; 2016 Jan; 34(1):67-76. PubMed ID: 26602268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
